Teenagers with type 1 diabetes now have the first randomized trial evidence that an SGLT2 inhibitor can protect their kidneys ...

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.

Eli Lilly’s once-daily oral pill orforglipron outperformed oral semaglutide in reducing blood sugar and body weight over 52 ...

A head-to-head trial of ADHD treatments finds dexamphetamine and methylphenidate equally effective, with notable differences ...

A study reveals dietary coaching aids weight loss equally in individuals with high and low genetic obesity risk, challenging ...

July 17, 2026 expert reaction to study looking at focal therapy (using a heat-based treatment (high intensity focused ultrasound, HIFU) or a freezing-based treatment (cryotherapy) ...

Evidence supports cannabis-based therapies for a limited number of conditions. Here’'s what clinicians should know — and tell ...

Infection control refers to the protocols and mechanisms that help to guarantee the safety of both the patient and provider; ...

The FDA just approved a new drug for use in ER+/HER2- metastatic breast cancer, based on a large study led by Fred Hutch's Dr. Sara Hurvitz. The new drug, gedatolisib, is a multi-targeted kinase ...

Instead, they actively downregulate the core behavioral features of BED, significantly reducing active binge eating episodes, loss-of-control eating, and emotional eating patterns. Drugs commonly used ...

HEALEY ALS Platform Trial so far Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027 Completion of recruitment materially de-risks execution of Neurizon's lead ...

An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial ...